Owning several biotech stocks is not, by itself, a diversified portfolio. A sound approach starts with your entire mix of stocks, bonds, cash and other assets, then examines concentration inside the stock allocation. Within the biotech sleeve, spread exposure across companies whose products, clinical stages, therapeutic areas and financing needs are not all dependent on the same event. Keep the allocation consistent with your time horizon, ability to absorb loss and understanding of clinical evidence; no official source establishes a universally safe biotech percentage, position size or stock count.
The U.S. Securities and Exchange Commission (SEC) describes diversification at two levels: across asset classes and within each class. Its October 5, 2026 World Investor Week bulletin calls diversification and asset allocation “important pillars of smart, resilient investing,” while also making clear that diversification cannot guarantee protection from losses. The biotech-specific framework below applies those general principles to a sector in which evidence, regulation and financing can change a company’s prospects quickly.
As an Amazon Associate I earn from qualifying purchases.
What diversification means when you buy individual biotech stocks
Diversification is a risk-management process, not a target number of ticker symbols. You are trying to avoid having one company, one scientific thesis, one regulatory decision or one broad market exposure determine the outcome of your finances.
Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Clear out junk files and repair common Windows errors3Scan for outdated or missing drivers - takes under a minuteSpread risk across asset categories first
Before counting biotech holdings, list the portfolio’s exposure to broad categories such as stocks, bonds, cash and any other investments you own. The SEC’s investor guidance treats allocation among categories as separate from diversification within a category. A portfolio made entirely of ten biotech companies still has concentrated exposure to equities and to one industry. Adding one biotech company to a portfolio dominated by a different stock sector may change company exposure without materially changing the portfolio’s overall asset mix.
#1 Best Overall
- Compact & Portable Design: This Small Excel, Word, PowerPoint, & Windows Cheat Sheet Mouse Pad measures 11.8" x 9.8", offering a portable mouse pad. Its compact size fits in bags or laptop cases, suitable for professionals, students, or travelers.
- Multi-Software Shortcut Guide: Featuring essential shortcut keys for Excel, Word, PowerPoint, & Windows, this small mouse pad provides a quick reference for frequently used shortcuts, offering a reference designed to support workflow efficiency
- Smooth & Precise Surface: The finely-textured surface ensures precise mouse control, allowing for smooth and accurate movement during work or gaming sessions.
- Durable & Non-Slip Design: This Multi-Software Shortcut Mouse Pad features stitched edges to reduce fraying. The non-slip rubber base helps keep it securely in place, and the water-resistant fabric allows for easier maintenance.
- Clear Print Quality: Displays high-resolution printing intended to remain legible through regular use and cleaning
Make the inventory at the household level where practical. Include workplace retirement accounts, taxable accounts, inherited assets and cash reserves if they are part of the money you may need for the same goals. A holding that looks small in one account can be large when all accounts are combined.
| Question | What to examine | Why it matters for biotech |
|---|---|---|
| Asset-category mix | Stocks versus bonds, cash and other categories | Several biotech shares cannot diversify non-stock risk or provide a cash reserve for near-term spending. |
| Stock-sector mix | Biotech and health care relative to other industries | Clinical, reimbursement and regulatory shocks can affect many companies in the same industry. |
| Account and currency exposure | Where assets are held and which currencies or markets they depend on | Tax, liquidity and market risks can remain concentrated even when company names differ. |
Then spread exposure within stocks
Inside the stock allocation, ask whether a few companies account for most of the value or most of the potential gain or loss. The SEC’s asset-allocation guide uses a general example in which four or five individual stocks are not enough to diversify the stock portion and says that at least a dozen carefully selected individual stocks are needed to be truly diversified. That statement is an illustrative guide for general stock investing—not a biotech rule, a guarantee, or a recommendation for your circumstances.
The SEC also warns that “It can be risky to invest heavily in shares of any individual stock.” A biotech position can become heavy without a new purchase: a successful trial can increase its market value, or declines elsewhere can make it a larger percentage of the portfolio. Review concentration by current market value, not only by the amount originally invested.
Free tools Windows power users keep installed
One-click scans. No signup required.
Several names can still share the same risk
Biotech diversification has an additional layer. Companies that appear unrelated by ticker may depend on similar events: a particular clinical endpoint, a common therapeutic area, the same type of manufacturing capacity, a narrow group of specialist physicians, or continued access to equity financing. If one event can damage several holdings at once, the names are not independent for the risk that concerns you.
This is an analytical application of the SEC’s general diversification principle and the FDA’s staged development process, not a formal SEC or FDA scoring system. Use it to identify correlations that a simple company-counting exercise misses.
Why a biotech company’s development stage matters
Individual biotech stocks are tied to products that must generate evidence and pass regulatory review. The FDA describes a progression from preclinical work to human clinical studies and then application review. A stage tells you what kind of evidence is being collected; it does not predict a stock’s return or guarantee approval.
Preclinical work
Preclinical testing occurs before a candidate is tested in people. Laboratory and animal work can inform whether a candidate is suitable for human studies, but a promising preclinical result is not evidence that the treatment will be safe or effective in patients. A company with only preclinical programs may face a long period without human data, along with the possibility that a candidate never enters a trial.
Phase 1
Phase 1 studies commonly focus on safety, dose and how the product behaves in the body. They may provide early signals, but they are generally not designed to establish the effectiveness needed for routine clinical use. A positive safety result therefore leaves substantial scientific and regulatory questions open.
Phase 2
Phase 2 studies seek preliminary evidence of effectiveness while continuing to study short-term risks. Design, patient selection and endpoints vary by product and indication. A signal in Phase 2 can fail to replicate later, and a trial can produce safety findings that change the development plan.
Rank #2
- [MULTIFUNCTIONAL]You'll get 2 pieces computer monitor memo boards that you can stick on the left and right edges of your monitor, and they're the perfect office desk organizers and accessories. Computer monitor side panels desktop organizer are suitable for home work or office,bringing convenience. Desktop memo is used to organize meeting memos, important messages, business cards, planning notes.Paste on the message board to keep track of important things and to-do items to prevent forgetting.
- [🌟HIGHLY QUALITY] The material of computer screen side note holder is transparent acrylic. Durable, simple, stylish, light weight, easy to use, not easy to fall off or break. This cute office supplies for women desk can be used for a long time. This computer desk accessories is waterproof and dirt resistance, and look simple and stylish. The transparent acrylic sticky note holder as cubicle accessories is easy to notice the context of your sticky notes.
- [📋Easy to use] Office must haves cool office gadgets for desk ready to tear, easy to install and remove, not easy to leave traces. You only need to peel off the protective film on the surface of the computer side board memo, wipe off the dust on the edge of the computer monitor, and then stick the desk essentials for women office on the right or left side of the tape, and you're done. A perfect gift for your colleagues, friends or classmates and family members or relatives
- [🏢MULTI-SCENE USE] This desk supplies computer memo board can be applied to home and office, clear your office decor for women, suitable for most computer monitors, screens and cabinets, you can put it where you think, this cute office decor serve as a reminder. Stick on the computer side. It’s a good office gadgets can remind work improve office productivity. Pasted cabinets, dressers, refrigerators, walls, etc as cubicle accessories. To make life more orderly.
- [💌NOTE] The adhesive force of the computer sticky note holder is very strong. It can not be directly pasted on the computer screen. It should pasted on the black edge of the screen. Narrow edge not recommended!!! If you are not satisfied with your purchase, or if the product is damaged or broken in transit, please let us know immediately. We will promptly solve your problem.
Phase 3
Phase 3 studies gather additional effectiveness and safety information to support an assessment of overall benefit and risk. They are often larger or more confirmatory, but a Phase 3 program is still evidence gathering rather than proof of approval, commercial demand or investor profit.
FDA review and special pathways
During review, the FDA evaluates submitted evidence and the product’s benefits and risks. Some regulatory pathways can rely on surrogate or earlier clinical endpoints in qualifying circumstances. Such a pathway can speed or structure review, but a designation or endpoint should not be treated as equivalent to established clinical benefit or a guarantee of market success.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →The FDA can place a clinical study on hold for safety concerns or deficient protocols. A hold, a request for additional analysis or a change in trial design can alter timing and cash needs. These are regulatory facts; the effect on a particular stock depends on its balance sheet, pipeline and valuation.
A step-by-step framework for diversifying a biotech allocation
1. Map the whole portfolio before selecting names
- List every investment account. Record each holding’s current value, not just contributions.
- Classify each holding. Mark it as an individual stock, pooled equity vehicle, bond or cash-like holding, or another category.
- Aggregate duplicates. A fund may already own a company you are considering; include that indirect exposure in your review.
- Identify money with a near-term job. Emergency reserves, tuition, taxes and other near-term needs should not depend on a volatile clinical outcome.
- Write the role of biotech in one sentence. For example, it might be a limited, high-uncertainty part of long-term equity exposure. If you cannot describe the role, pause before buying.
The SEC-led 2023 investor bulletin advises investors to consider carefully how much, if any, of a portfolio to devote to speculative or complex investments. It does not provide a universal biotech allocation, and neither does the material on FDA development stages.
2. Set personal constraints without borrowing a universal percentage
Decide how a large decline would affect your goals, cash flow and ability to remain invested. Relevant constraints include:
- time until the money is needed;
- income stability and emergency savings;
- tax consequences of selling;
- ability to read trial protocols, filings and safety disclosures;
- existing exposure through funds, employment or a spouse’s assets; and
- whether you could continue your plan after a disappointing trial or offering.
These factors can justify a smaller or zero allocation to individual biotech stocks. They cannot establish a correct percentage for every investor.
Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallCrashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minute3. Build a company-exposure inventory
For each prospective or existing holding, record the position value and the company’s share of your total stock allocation. Then note whether the company has one lead program or several, whether revenue already exists, and how much of the valuation depends on future products. Keep company concentration separate from the broader question of whether your portfolio has enough exposure to other asset categories.
4. Map development dependencies
Create a simple matrix for the risks that could affect more than one holding. Useful prompts include:
| Dependency | Questions to ask | Interpretation |
|---|---|---|
| Clinical stage | Are several companies awaiting early safety data, preliminary efficacy, or confirmatory results at the same time? | Shared timing can create correlated price reactions even when the medicines differ. |
| Therapeutic area | Do the companies target the same disease, patient population or mechanism? | New safety information or treatment standards may affect several names. |
| Endpoint and trial design | Do programs rely on similar surrogate endpoints, enrollment assumptions or comparator treatments? | A change in how evidence is viewed can have a wider effect than one company’s headline result. |
| Financing | Will several companies need to raise capital before their next milestone? | Weak markets can make dilution or delayed programs more likely across the group. |
| Commercial path | Would products compete for the same specialists, sites, payers or manufacturing capacity? | Approval would not remove launch, pricing or supply-chain concentration. |
This matrix is an editorial decision aid, not a validated diversification metric. Its purpose is to expose shared assumptions before you treat several stocks as independent bets.
Rank #3
- Stay Organized with Ease: Our To Do List Notepad provides multiple sections with plenty of space to jot down all of your important tasks.A versatile office supply perfect for daily task management, helping you keep track of everything that needs to be done and prioritize effectively.
- Achieve Your Productivity Goals: Begin each day on a positive note, reminding you of your potential, strength, and the significance of staying focused on your goals. Our Daily Checklist Notepad is the ultimate tool to streamline your daily planning and elevate your productivity. With a clear and concise overview of your tasks, you can effortlessly prioritize what truly matters and make consistent strides towards achieving your goals.
- Reliable and Stylish: Our to do list planner combines functionality with durability. With a transparent PP cover, the inner pages are well-protected from dirt and wear. Additionally, the back cover is crafted with thick paperboard, offering a stable surface for your writing needs. Each notepad includes 52 pages of high-quality, 100gsm paper, which is thick and non-bleeding, resulting in a smooth and enjoyable writing experience.
- Versatile Use: This daily checklist notepad, suitable for teacher supplies and a wide range of applications, proves invaluable in various settings including work, school, and home. Whether you need to organize your daily tasks, plan a project, or create a grocery list, this notepad serves as the ideal tool. Its compact size ensures easy portability, allowing you to conveniently carry it with you throughout your day.
- Perfect Present for Anyone: Our Daily To-Do List Notepad is the perfect present for those who value organization and productivity. With its stylish design and versatility, this office desk accessory is also a practical addition to school supplies. Suitable for students, professionals, and homemakers alike, it helps keep tasks and priorities in check effortlessly.
5. Evaluate evidence, not just labels
For each company, identify the most decision-relevant evidence and its limitations:
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
- What has been shown in preclinical work or human studies?
- Is the result a safety observation, a preliminary efficacy signal or a later-stage comparison?
- How many patients, sites and follow-up periods are represented in the disclosed data?
- What endpoint was measured, and was it a surrogate or a direct clinical outcome?
- What did the company say about adverse events, discontinuations and missing data?
- What remains for the next trial, regulatory interaction or filing?
Do not substitute a phase label for the underlying evidence. Exact trial requirements and designs differ by product and indication. The FDA’s statement that clinical-trial results are the “single most important factor” in approval or disapproval concerns the drug approval process, not the investment merits of the sponsoring company.
6. Size positions using a written rule
Instead of choosing a position size from a headline percentage, write a rule that connects the purchase to your constraints. A rule might specify a maximum amount you are willing to lose without changing essential goals, how you will treat an offering or merger, and what evidence would make you reduce exposure. Keep the rule consistent across companies unless you can explain why a difference is justified.
A position can become oversized after a rapid price increase. Decide in advance whether you will rebalance on a calendar, when a holding exceeds a self-imposed limit, or when the investment thesis changes. The rule is a discipline, not a promise that losses will be limited.
7. Add diversification outside the biotech sleeve
If your portfolio lacks other stock sectors, bonds or cash, address that structural issue separately. Buying another biotech name may increase the same risk you already have. Broad funds or other asset categories can be tools for reducing company-specific exposure, but the appropriate mix depends on your objectives and circumstances; this guide does not select a product or prescribe an allocation.
8. Rebalance and document the reason
Keep a dated record of each purchase, the evidence then available, the expected next event and the reason the position belongs in the portfolio. On review, compare current weights with your written limits and check whether the company’s development plan has changed. Rebalancing can involve selling a winner, adding to an underweight category or leaving a position alone; the decision should follow the plan rather than a reaction to a single headline.
How many biotech stocks should you own?
There is no official number that makes a biotech portfolio diversified. The SEC’s “at least a dozen carefully selected individual stocks” example addresses diversification of a general stock allocation and should not be converted into a rule that every investor needs a dozen biotech companies. A dozen companies concentrated in one disease area or clinical event can share more risk than a smaller, deliberately varied group.
Stock count is useful only when paired with exposure and dependency checks. Ask:
- What percentage of the total portfolio and stock allocation would be lost if one company failed?
- How many holdings depend on the same milestone, endpoint, financing window or market?
- Would a bad result in one program force you to sell other companies because they need capital at the same time?
- Can you follow every company’s filings, trial updates and cash position well enough to maintain the plan?
If the answer to the last question is no, adding names may create the appearance of diversification while reducing your ability to monitor risk.
Rank #4
- 【Adjustable & Ergonomic】：This laptop stand can be adjusted to a comfortable height and angle according to your actual needs, letting you fix posture and reduce your neck fatigue, back pain and eye strain. Very comfortable for working in home, office and outdoor.
- 【Sturdy & Protective】 ：Made of sturdy metal, it can support up to 17.6 lbs (8kg) weight on top; With 2 rubber mats on the hook and anti-skid silicone pads on top & bottom, it can secure your laptop in place and maximum protect your device from scratches and sliding. Moreover, smooth edges will never hurt your hands.
- 【Heat Dissipation】 ：The top of the laptop stand is designed with multiple ventilation holes. The open design offers greater ventilation and more airflow to cool your laptop during operation other than it just lays flat on the table.
- 【Portable & Foldable】：The foldable design allows you to easily slip it in your backpack. Ideal for people who travel for business a lot.
- 【Broad Compatibility】：Our desktop book stand is compatible with all laptops from 10-15.6 inches, such as MacBook Air/ Pro, Google Pixelbook, Dell XPS, HP, ASUS, Lenovo ThinkPad, Acer, Chromebook and Microsoft Surface, etc.Be your ideal companion in Home, Office & Outdoor.
Comparing ways to hold biotech exposure
| Approach | Main exposure | Potential advantage | Key limitation |
|---|---|---|---|
| One or two individual companies | Very concentrated company and program risk | Simple to track and highly specific | A single trial, financing or regulatory event can dominate results. |
| A deliberately varied basket of individual companies | Company-specific risk spread across several programs | Allows differences in stage, modality and commercial path to be expressed | Requires research, monitoring and control of shared dependencies; it remains equity and sector exposure. |
| Broad health-care or equity vehicle | Many companies, often with non-biotech businesses included | Reduces dependence on one company without requiring security-by-security selection | May not provide the precise biotech exposure or control you want. |
| Biotech-focused pooled vehicle | A basket selected under the vehicle’s mandate | Can spread company-specific risk and simplify administration | Still subject to sector and market risk, fees, portfolio overlap and the manager’s methodology. |
The choice is not between “diversified” and “undiversified” labels. Examine what each approach actually owns, how much it overlaps with your other accounts and whether you can tolerate its risks.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Due-diligence checklist for each individual biotech stock
Science and clinical evidence
- What disease and patient population is being treated?
- What is the mechanism or product type, and what evidence supports it?
- Which phase is the lead program in, and what was the study designed to establish?
- Are the endpoint, comparator and follow-up adequate for the claim being made?
- What safety signals, withdrawals or protocol changes have been disclosed?
Regulatory status
- What interaction with the FDA or another regulator has actually occurred?
- Is a designation being described as a process benefit rather than proof of efficacy?
- Could a hold, request for additional information or review issue delay the next milestone?
- Does the program rely on a surrogate or earlier endpoint, and what confirmatory work would remain?
Financial durability
- How much cash is available and what spending is required for the next meaningful milestone?
- Is another equity offering, debt raise, partnership or royalty transaction likely to be needed?
- Would dilution or a changed partnership alter your original thesis?
- Does the company have revenue, and if so, does it depend on one product or customer?
Portfolio fit
- Does the position add a genuinely different source of risk, or duplicate an existing program?
- How large would the exposure be after including indirect holdings?
- What would you do if the next result is delayed, mixed or negative?
Common mistakes and how to correct them
Counting tickers instead of exposures
Problem: You own many names but most of the value is in two companies or one therapeutic theme.
Correction: Calculate each holding’s share of the total portfolio and stock allocation, then map shared clinical and financing dependencies.
Treating a phase milestone as a probability of success
Problem: A Phase 2 or Phase 3 announcement is read as evidence that approval or revenue is likely.
Correction: Identify what the study actually measured, its limitations and the next evidence required. A later phase is not a promise.
Assuming an FDA designation guarantees commercial value
Problem: A special pathway or surrogate endpoint is described as if it establishes clinical benefit or market demand.
Correction: Separate the regulatory process from questions about effectiveness, labeling, reimbursement, competition and execution.
Ignoring correlated financing risk
Problem: Several pre-revenue companies need capital at the same time, so a weak market affects all of them.
The Tool Desk
Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Correction: Record cash needs and likely milestones for each company and treat financing assumptions as a shared risk when they overlap.
Best Value
- Twin-Ball Design : Hiacry gel pen features a double ball conical tip that reduces writing resistance and provides a stable and smooth writing experience. 0.7mm quick drying black ink ensures no jumping, leakage or seepage.
- Quick-Dry Long Lasting Ink：0.7mm black ink can slide effortlessly, dry immediately, & is not easily dirty. It has a high-capacity reservoir (up to 1300 meters), which is very suitable for left-handed & right-handed users.
- Sleek Design for Journaling & Planning: Engineered with a low center of gravity and precision tip for steady ink flow, these journaling pens excel at note-taking, sketching, planning, and more. They combine stylish pens with top-tier performance.
- Rolling Ball Design：The pocket clip with roll ball design can be easily attached to notebook pockets and binders, in addition, the fidget on the pen clip is also a small toy for your daily thinking to relieve stress.
- Comfortable Non-Slip Grip：The ergonomic pen barrel has a soft rubberized coating for a comfortable, non-slip grip, so you won't get fatigued even after long hours of writing.
Using a fixed biotech percentage as a substitute for planning
Problem: A rule copied from another investor is treated as suitable regardless of goals or capacity for loss.
Correction: Set the role and limits from your own horizon, liquidity needs, existing exposure and ability to understand the evidence. The SEC guidance asks investors to consider carefully how much, if any, of a portfolio belongs in speculative or complex investments.
Letting a winner become the plan
Problem: A rising stock grows into a dominant position, and the original risk limit disappears.
Recommended Free Tools
Correction: Review weights on a schedule and apply the written rebalancing rule, including the tax consequences of a sale.
Worked examples without a one-size-fits-all answer
Example: many names, one event
An investor owns eight early-stage companies, all awaiting clinical readouts within the same year and all likely to raise capital before approval. The ticker count looks broad, but the portfolio is exposed to a common timing and financing cycle. A better review would separate the companies by stage, evidence quality, cash runway and dependence on the same endpoint, then compare the resulting exposure with the investor’s non-biotech assets.
Example: one successful holding becomes too large
An investor begins with several small positions. One company’s market value rises sharply after favorable data and now represents most of the biotech allocation. The company may still be attractive, but the risk has changed. The investor should compare the current weight with the written limit, assess taxes and liquidity, and decide whether rebalancing is consistent with the plan rather than assuming the earlier purchase size remains appropriate.
Example: biotech is not the portfolio’s main problem
An investor has three biotech stocks but almost all household wealth is in individual equities, with little cash for a near-term goal. Adding a fourth biotech stock does not solve the asset-category or liquidity issue. The first action is to map the whole portfolio and match assets to the timing of the goals; only then should the investor decide whether individual biotech exposure belongs at all.
The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →How to monitor a biotech portfolio after buying
- Set review dates. Use a regular schedule for weights, cash runway and portfolio overlap instead of reacting to every price movement.
- Track evidence events. Record trial starts, enrollment changes, data releases, regulatory meetings, submissions and decisions.
- Read the details behind headlines. Compare the announced result with the prespecified endpoint, safety data, follow-up and statistical context.
- Update dependencies. A partnership, discontinued program or change in trial design can make two holdings more or less correlated.
- Recheck the whole portfolio. Include indirect exposure and changes in other accounts before deciding that a biotech position is still within limits.
- Use a thesis-based exit rule. Sell or reduce when the evidence, financing path, portfolio role or personal circumstances no longer fit the written plan—not merely because a stock moved on a single day.
What diversification can and cannot do
Diversification can reduce the damage caused by one company or one investment performing poorly, especially when exposures are genuinely different. It cannot prevent a broad equity decline, eliminate sector-wide regulatory or financing shocks, make an unsuccessful drug work, or guarantee a positive return. The SEC’s general guidance is explicit that diversification is not a guarantee against loss.
FDA stages help you describe what is known and what remains uncertain about a product. They do not turn a clinical milestone into an investment forecast. Keep those two questions separate: What evidence does the regulator need? and How much of my financial plan should depend on this company?
A practical decision rule
Before purchasing an individual biotech stock, you should be able to state, in writing:
- where the position fits in your overall asset allocation;
- how large it may become before you review or rebalance;
- which clinical, regulatory and financing assumptions drive its value;
- which other holdings share those assumptions;
- what evidence would strengthen or weaken the thesis; and
- how you would meet your goals if the company fails to deliver.
If you cannot answer those questions, the issue is not that you need a particular number of biotech stocks. You need a clearer portfolio plan or a simpler way to obtain the exposure. Individual biotech shares can be one component of a diversified strategy only when they are sized within the whole portfolio, evaluated for shared development risks and kept subordinate to the investor’s actual goals and capacity for loss.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
